Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Co.'s product candidates are derived from donor cells and pre-manufactured, stored frozen and ship to a patient's treatment location. Co.'s lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. We show 4 historical shares outstanding datapoints in our ARTV shares outstanding history coverage, used to compute ARTV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARTV market cap history over the course of time is important for investors
interested in comparing ARTV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARTV versus a peer is one thing; comparing
ARTV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARTV can fluctuate over the course of history.
With this page we aim to empower investors researching ARTV by allowing them to research the ARTV market cap history. |
Free ARTV Email Alerts:
Video: The Importance of Market Cap
